We are very pleased to welcome Menarini Pharmaceutical Group as a FH23 partner.

The Menarini Pharmaceutical Group, with headquarters in Florence, is present in 140 countries worldwide to date, with € 4.155 billion in revenue and 17,700 employees. With 9 centres for Research & Development, Menarini’s products are present in the most important treatment areas: cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesic products. Pharmaceutical production is carried out in the Group’s 18 manufacturing plants, located in Italy and abroad, which produce over 578 million packets of product a year and distribute to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients throughout the world. Menarini has reaffirmed its commitment to digital acceleration in pharmaceutical and healthcare by announcing a Platinum sponsorship for Frontiers Health 2023, a leading event in digital health innovation. 

This partnership underscores our dedication to digital therapeutics, cutting-edge technologies, healthcare transformation, and investments in the digital health ecosystem. It also strengthens our commitment to people development, aiming to arm our employees with the most recent digital health knowledge. Dr. Steven Januar Kusmanto (Global Digital & Marketing Excellence Director), asserts that "this collaboration aligns seamlessly with Menarini's global strategic vision for digital marketing. It will substantially strengthen our pursuit of excellence in digital marketing initiatives."

Join FH23 in Rome and online to learn more about Menarini Pharmaceutical Group!